Biomarker Testing Services Market Size, Share and Growth Outlook, 2026

Biomarker Testing Services Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Biomarker Testing Services Market size is forecast to increase from $881.88 Million in 2026 to $1736.67 Million in 2034 at a CAGR of 8.84% between 2026 and 2034.

The Biomarker Testing Services market report provides detailed analysis and outlook of Biomarker Testing Services segments including By Service Type (Biomarker Research Services, Validation & Testing Services, Companion Diagnostics, Bioanalytical Services), By Disease Indication (Oncology, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Infectious Diseases), By End-User (Hospitals, Diagnostic Centers, Specialty Clinics, Pharmaceutical & Research Institutions), By Clinical Phase (Preclinical Phase, Clinical Phases, Post-Marketing Phase) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Biomarker Testing Services Industry Overview

Expansion of Central Laboratory Infrastructure Strengthens Clinical Trial Biomarker Testing

The Biomarker Testing Services industry is experiencing significant growth as pharmaceutical companies, biotechnology organizations, and clinical research sponsors increasingly rely on advanced biomarker analysis to support precision medicine and drug development programs. Biomarker testing services have become essential for patient stratification, treatment monitoring, clinical trial enrollment, and therapeutic response assessment. A major development in the industry is the expansion of Laboratory Corporation of America Holdings’ central laboratory facility in Geneva, Switzerland. The enhanced infrastructure is specifically dedicated to scaling global clinical trial biomarker testing operations, with a strong focus on automated flow cytometry and multiplex genomic assay services for oncology studies conducted across Europe. The investment reflects the growing demand for high-throughput biomarker testing platforms capable of supporting increasingly complex clinical trial designs and large-scale precision oncology programs.

Blood-Based Screening Services Expand Preventive Healthcare Applications

The growing adoption of minimally invasive biomarker testing is creating new opportunities for service providers in preventive medicine and early disease detection. Blood-based biomarker testing is increasingly being utilized to identify disease-associated molecular signatures before clinical symptoms become apparent. Quest Diagnostics strengthened its position in this area through a commercial agreement with Universal DX to provide advanced blood-based biomarker testing services for colorectal cancer screening. Leveraging its extensive physician network and centralized laboratory infrastructure, Quest will offer testing services designed to support the early detection of adenomas and colorectal cancer-related biomarkers. The expansion of blood-based screening services reflects broader industry trends favoring non-invasive diagnostics that improve patient compliance, facilitate earlier intervention, and support population-wide screening initiatives. As healthcare systems increasingly prioritize preventive care, biomarker testing services are becoming a critical component of early disease detection strategies.

Personalized MRD Monitoring Advances Precision Oncology Services

Precision oncology continues to drive innovation within the Biomarker Testing Services market, particularly through personalized approaches to cancer monitoring and recurrence detection. NeoGenomics Laboratories expanded its oncology testing portfolio through the introduction of NeoRadar™, a specialized minimal residual disease testing service. The platform utilizes a custom patient-specific next-generation sequencing assay that tracks individualized tumor biomarkers over time. By monitoring unique molecular signatures associated with a patient's cancer, the service can detect recurrence events weeks before visible symptoms or conventional imaging findings emerge. Personalized MRD testing is increasingly recognized as a valuable tool for evaluating treatment effectiveness, monitoring disease progression, and guiding post-treatment clinical management. As oncology care becomes increasingly individualized, advanced biomarker testing services capable of delivering highly specific and actionable molecular insights are becoming integral to modern cancer management strategies.

Biomarker Testing Services Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Biomarker Testing Services market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Laboratory Corporation of America Holdings , Quest Diagnostics Incorporated, Eurofins Scientific SE, Charles River Laboratories International, Inc., NeoGenomics Laboratories, Inc., Sonic Healthcare Limited, Centogene N.V., Genomic Health, Inc. , Myriad Genetics, Inc., Bio-Reference Laboratories, Inc.. The Biomarker Testing Services market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Biomarker Testing Services industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Biomarker Testing Services Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Biomarker Testing Services companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Biomarker Testing Services markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Biomarker Testing Services Market Competitive Benchmarking and Company Analysis

Leading companies in Biomarker Testing Services industry include- Laboratory Corporation of America Holdings , Quest Diagnostics Incorporated, Eurofins Scientific SE, Charles River Laboratories International, Inc., NeoGenomics Laboratories, Inc., Sonic Healthcare Limited, Centogene N.V., Genomic Health, Inc. , Myriad Genetics, Inc., Bio-Reference Laboratories, Inc.. The Biomarker Testing Services market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Biomarker Testing Services Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Biomarker Testing Services market remains one of the strongest-performing segments in the country.
The US Biomarker Testing Services Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Biomarker Testing Services market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Biomarker Testing Services industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Biomarker Testing Services markets

Canada's strong Biomarker Testing Services sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Biomarker Testing Services market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Biomarker Testing Services Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Biomarker Testing Services market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Biomarker Testing Services population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Biomarker Testing Services industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Biomarker Testing Services market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Biomarker Testing Services sales through 2034

France Biomarker Testing Services companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Biomarker Testing Services Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Biomarker Testing Services distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Biomarker Testing Services Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Biomarker Testing Services market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Biomarker Testing Services industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Biomarker Testing Services industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Biomarker Testing Services Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Biomarker Testing Services market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Biomarker Testing Services market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Biomarker Testing Services Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Biomarker Testing Services Market Segmentation

By Service Type
Biomarker Research Services
Validation & Testing Services
Companion Diagnostics
Bioanalytical Services
By Disease Indication
Oncology
Cardiovascular Disorders
Neurological Disorders
Immunological Disorders
Infectious Diseases
By End-User
Hospitals
Diagnostic Centers
Specialty Clinics
Pharmaceutical & Research Institutions
By Clinical Phase
Preclinical Phase
Clinical Phases
Post-Marketing Phase

Top Companies in Biomarker Testing Services Industry

Laboratory Corporation of America Holdings
Quest Diagnostics Incorporated
Eurofins Scientific SE
Charles River Laboratories International, Inc.
NeoGenomics Laboratories, Inc.
Sonic Healthcare Limited
Centogene N.V.
Genomic Health, Inc.
Myriad Genetics, Inc.
Bio-Reference Laboratories, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025